Show simple item record

Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans

dc.contributor.authorSchechter, Shula A.
dc.contributor.authorBresler, Scott C.
dc.contributor.authorPatel, Rajiv M.
dc.date.accessioned2020-10-01T23:29:17Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-10-01T23:29:17Z
dc.date.issued2020-10
dc.identifier.citationSchechter, Shula A.; Bresler, Scott C.; Patel, Rajiv M. (2020). "Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans." Journal of Cutaneous Pathology 47(10): 913-916.
dc.identifier.issn0303-6987
dc.identifier.issn1600-0560
dc.identifier.urihttps://hdl.handle.net/2027.42/162705
dc.description.abstractBackgroundCellular dermatofibromas (CDFs) and dermatofibrosarcoma protuberans (DFSP) can be challenging to differentiate from one another. Morphologically, both entities commonly extend into the subcutis, exhibit high cellularity with limited cytologic atypia and have a mixed fascicular‐to‐storiform growth pattern. We sought to evaluate the significance of fat necrosis with an associated lymphocytic infiltrate as a histopathologic clue for distinguishing CDFs from DFSP.MethodsWe identified cases in our pathology database with a primary diagnosis of CDF or DFSP. Punch or excisional biopsy specimens with extension into the subcutis were selected. Previously biopsied lesions and specimens that did not interact with the subcutis were excluded. Histopathologic features were evaluated in hematoxylin and eosin stained sections.ResultsFat necrosis with lymphocytic infiltrate was present in 20/20 cases of CDF. None of the 20 DFSP cases had fat necrosis with lymphocytic infiltrate although 4/20 had fat necrosis alone.ConclusionsFat necrosis with associated lymphocytic response can aid in the distinction between CDF and DFSP.
dc.publisherBlackwell Publishing Ltd.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherfibrous histiocytoma
dc.subject.otherdermatofibrosarcoma protuberans
dc.subject.othercellular dermatofibroma
dc.subject.otherfat necrosis
dc.subject.otherhistopathology
dc.titleFat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDermatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/162705/2/cup13744_am.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/162705/1/cup13744.pdfen_US
dc.identifier.doi10.1111/cup.13744
dc.identifier.sourceJournal of Cutaneous Pathology
dc.identifier.citedreferenceCalonje E, Mentzel T, Fletcher CD. Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. Am J Surg Pathol. 1994; 18 ( 7 ): 668 ‐ 676.
dc.identifier.citedreferenceHan TY, Chang HS, Lee JH, Lee WM, Son SJ. A clinical and histopathological study of 122 cases of dermatofibroma (benign fibrous histiocytoma). Ann Dermatol. 2011; 23 ( 2 ): 185 ‐ 192.
dc.identifier.citedreferenceGaufin M, Michaelis T, Duffy K. Cellular dermatofibroma: clinicopathologic review of 218 cases of cellular dermatofibroma to determine the clinical recurrence rate. Dermatol Surg. 2019; 45 ( 11 ): 1359 ‐ 1364.
dc.identifier.citedreferenceFletcher CD, Hogendoorn P, Mertens F, Bridge J. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013.
dc.identifier.citedreferenceHoesly PM, Lowe GC, Lohse CM, Brewer JD, Lehman JS. Prognostic impact of fibrosarcomatous transformation in dermatofibrosarcoma protuberans: a cohort study. J Am Acad Dermatol. 2015; 72 ( 3 ): 419 ‐ 425.
dc.identifier.citedreferenceGoldblum JR, Tuthill RJ. CD34 and factor‐XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol. 1997; 19 ( 2 ): 147 ‐ 153.
dc.identifier.citedreferenceSachdev R, Sundram U. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and factor XIIIa. J Cutan Pathol. 2006; 33 ( 5 ): 353 ‐ 360.
dc.identifier.citedreferenceBowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000; 88 ( 12 ): 2711 ‐ 2720.
dc.identifier.citedreferenceKreicher KL, Kurlander DE, Gittleman HR, Barnholtz‐Sloan JS, Bordeaux JS. Incidence and survival of primary dermatofibrosarcoma protuberans in the United States. Dermatol Surg. 2016; 42 ( Suppl 1 ): S24 ‐ S31.
dc.identifier.citedreferenceCriscito MC, Martires KJ, Stein JA. Prognostic factors, treatment, and survival in dermatofibrosarcoma protuberans. JAMA Dermatol. 2016; 152 ( 12 ): 1365 ‐ 1371.
dc.identifier.citedreferenceVolpicelli ER, Fletcher CD. Desmin and CD34 positivity in cellular fibrous histiocytoma: an immunohistochemical analysis of 100 cases. J Cutan Pathol. 2012; 39 ( 8 ): 747 ‐ 752.
dc.identifier.citedreferenceHui P, Glusac EJ, Sinard JH, Perkins AS. Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma). J Cutan Pathol. 2002; 29 ( 7 ): 385 ‐ 389.
dc.identifier.citedreferenceChen TC, Kuo T, Chan HL. Dermatofibroma is a clonal proliferative disease. J Cutan Pathol. 2000; 27 ( 1 ): 36 ‐ 39.
dc.identifier.citedreferencePlaszczyca A, Nilsson J, Magnusson L, et al. Fusions involving protein kinase C and membrane‐associated proteins in benign fibrous histiocytoma. Int J Biochem Cell Biol. 2014 Aug; 53: 475 ‐ 481.
dc.identifier.citedreferenceCalonje E. Is cutaneous benign fibrous histiocytoma (dermatofibroma) a reactive inflammatory process or a neoplasm? Histopathology. 2000; 37 ( 3 ): 278 ‐ 280.
dc.identifier.citedreferenceZelger BG, Zelger B. Dermatofibroma (fibrous histiocytoma): an inflammatory or neoplastic disorder? Histopathology. 2001; 38 ( 4 ): 379 ‐ 381.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.